Education
About Us
Working with TipRanks
Follow Us
Petros Pharmaceuticals (PTPI)
OTHER OTC:PTPI
PTPI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $16.25
Previous CloseN/A
Volume1.29M
Average Volume (3M)514.86K
Market Cap
$897.41K
Enterprise Value-$8.04M
Total Cash (Recent Filing)$8.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.60
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-90.40
Shares Outstanding31,160,086
10 Day Avg. Volume453,438
30 Day Avg. Volume514,860
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market Cap-8.96
Enterprise Value/Revenue-0.47
Enterprise Value/Gross Profit-2.83
Enterprise Value/Ebitda0.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
Petros Pharmaceuticals News
PremiumCompany Announcements
Petros Pharmaceuticals Assigns Subsidiary Assets Amid Insolvency
PremiumCompany Announcements
Petros Pharmaceuticals Faces Nasdaq Delisting Notice
Bulls Say, Bears Say
Bulls Say
App Study ResultsPetros announced positive results from a small app comprehension study finding the vast majority of subjects understood the communication and messages from Petros’ App for self-selecting over-the-counter (OTC) Stendra.
Regulatory PathwayThe finalized ACNU pathway should further de-risk development and provide greater clarity in terms of regulatory standards, study designs and costs for development.
Bears Say
Strategic Shift ImpactThe strategic focus on platform technology is seen as a move away from biotechnology/pharmaceuticals development, impacting previous market expectations.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.11% Mutual Funds
0.13% Other Institutional Investors
99.89% Public Companies and Individual Investors
PTPI FAQ
What was Petros Pharmaceuticals’s price range in the past 12 months?
Petros Pharmaceuticals lowest stock price was $0.02 and its highest was $16.25 in the past 12 months.
What is Petros Pharmaceuticals’s market cap?
Petros Pharmaceuticals’s market cap is $897.41K.
When is Petros Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Petros Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Petros Pharmaceuticals overvalued?
According to Wall Street analysts Petros Pharmaceuticals’s price is currently Overvalued.
Does Petros Pharmaceuticals pay dividends?
Petros Pharmaceuticals does not currently pay dividends.
What is Petros Pharmaceuticals’s EPS estimate?
Petros Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Petros Pharmaceuticals have?
Petros Pharmaceuticals has 31,160,086 shares outstanding.
What happened to Petros Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Petros Pharmaceuticals?
Currently, no hedge funds are holding shares in PTPI
Company Description
Petros Pharmaceuticals
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.